FOLFOX

Phase 3Small molecule

FOLFOX is one of 438 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

437

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

MetastasisActive, not recruiting

Esophageal CancerActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Pancreatic Neuroendocrine TumorActive, not recruiting

Intrahepatic CholangiocarcinomaActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerRecruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 1/Phase 2

Active, not recruiting

MetastasisPhase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Pancreatic Neuroendocrine TumorPhase 3

Active, not recruiting

Intrahepatic CholangiocarcinomaPhase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 2/Phase 3

Active, not recruiting

Metastatic Colorectal CancerPhase 1

Recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

FOLFOX

AstraZeneca

Phase 3

5 2

Gemzar

GGynecologic Oncology Group

Medrol

1 4

Byetta

AstraZeneca

Preclinical

1 5

MS Contin

Merck & Co.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

ABI-007

Bristol-Myers Squibb

Preclinical

2 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Meglitinides

Sanofi

Preclinical

1 10

Chemotherapy Agents

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Advanced

NCT05718492

Phase 1/2Active, not recruiting

Chemotherapy

NCT04068610

Q1 2027

Phase 1Recruiting

Advanced or Metastatic Solid Tumors

NCT06179160

Phase 2Active, not recruiting

Metastatic Colorectal Cancer

NCT06106308

Phase 1Recruiting

Advanced or Metastatic Solid Tumors

NCT05836324

Phase 2Recruiting

Chemotherapy

NCT07192185

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer15 trials

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

Recruiting·UUniversity of Campania Luigi Vanvitelli·Phase 3·NCT07389265·480 enrolled

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

Completed· Pfizer logo

Pfizer·Phase 2·NCT00615056·171 enrolled

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting·CCelyad Oncology SA·Phase 1·NCT04991948·34 enrolled

Show 12 more trials

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT00116506·35 enrolled

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Recruiting·—·Phase 1/2·NCT07204574·40 enrolled

A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00494221·172 enrolled

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00399035·1,254 enrolled

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00778830·289 enrolled

FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT02128425·162 enrolled

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Active, not recruiting·CCardiff Oncology·Phase 2·NCT06106308·113 enrolled

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07318389·100 enrolled

A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Completed· Roche logo

Roche·Phase 1·NCT00851136·9 enrolled

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Terminated·OOncoMed Pharmaceuticals, Inc.·Phase 1·NCT03035253·16 enrolled

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07221357·990 enrolled

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Recruiting· Roche logo

Roche·Phase 1·NCT04929223·542 enrolled

Pancreatic Cancer5 trials

FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04167007·400 enrolled

Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer

Completed·—·Phase 2·NCT00786006·61 enrolled

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Terminated· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01632306·13 enrolled

Show 2 more trials

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

Unknown status·AAlliance for Clinical Trials in Oncology·Phase 2·NCT02839343·126 enrolled

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02923921·567 enrolled

Gastric Cancer4 trials

XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)

Terminated·—·Phase 3·NCT01748851·42 enrolled

FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer

Completed·YYale University·Phase 2·NCT00673673·39 enrolled

Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer

Completed·YYonsei University·Phase 2·NCT01283204·180 enrolled

Show 1 more trial

Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer

Unknown status·IInternational Group of Endovascular Oncology··NCT02002195·47 enrolled

Colorectal Cancer4 trials

A Study of Picoplatin in Colorectal Cancer

Unknown status·PPoniard Pharmaceuticals·Phase 1/2·NCT00478946·43 enrolled

A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

Withdrawn· Roche logo

Roche·Phase 2·NCT07323576

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00551213·67 enrolled

Show 1 more trial

Phase 2 Study of DKN-01 in Colorectal Cancer

Completed·LLeap Therapeutics, Inc.·Phase 2·NCT05480306·188 enrolled

Chemotherapy3 trials

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT04068610·61 enrolled

Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

Terminated·—·Phase 2·NCT03117972·54 enrolled

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Recruiting·SSun Yat-sen University·Phase 2·NCT07192185·30 enrolled

40 more indications

Intrahepatic Cholangiocarcinoma3 trials

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05535647·60 enrolled

Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)

Recruiting·FFudan University·Phase 2·NCT06860477·92 enrolled

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07353827·36 enrolled

Locally-advanced Rectal Cancer3 trials

Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

Not yet recruiting·JJ. W. A. Burger·Phase 3·NCT07472868·394 enrolled

Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer

Active, not recruiting·UUniversity of Rochester·Phase 2·NCT03781323·12 enrolled

Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

Not yet recruiting·ZZhejiang Cancer Hospital·Phase 3·NCT07074353·360 enrolled

Adenocarcinoma2 trials

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT01611857·49 enrolled

Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma

Unknown status·—·Phase 3·NCT02502370·100 enrolled

Advanced or Metastatic Solid Tumors2 trials

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting· Incyte logo

Incyte·Phase 1·NCT05836324·408 enrolled

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting· Incyte logo

Incyte·Phase 1·NCT06179160·710 enrolled

Esophageal Cancer2 trials

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00381706·245 enrolled

Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.

Terminated·CCentre Oscar Lambret·Phase 2·NCT01248299·105 enrolled

Rectal Cancer2 trials

A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer

Completed·SSir Mortimer B. Davis - Jewish General Hospital·Phase 2·NCT01274962·180 enrolled

A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

Unknown status·LLiz-Anne Lewsley·Phase 2·NCT04621370·48 enrolled

Stage III Colon Cancer2 trials

Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer

Completed·JJules Bordet Institute·N/A·NCT00994864·235 enrolled

Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery

Completed·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT00265811·2,559 enrolled

Advanced1 trial

A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents

Recruiting·SSun Yat-sen University·N/A·NCT05718492·100 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05702229·163 enrolled

Colon Cancer1 trial

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting· GSK logo

GSK·Phase 3·NCT05855200·892 enrolled

Paclitaxel1 trial

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Completed·FFujian Cancer Hospital·Phase 2·NCT02845908·90 enrolled

Colorectal Carcinoma1 trial

RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

Completed·UUniversity of Utah·Phase 1/2·NCT01047293·47 enrolled

Cancer1 trial

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Completed· Roche logo

Roche·Phase 2·NCT00959647·19 enrolled

Efficacy1 trial

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

Completed·MMedivation, Inc.·Phase 2·NCT00890305·171 enrolled

Biliary Tract Cancer1 trial

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

Not yet recruiting·FFudan University·Phase 2·NCT06919848·74 enrolled

Patients With Solid Tumors1 trial

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00502567·104 enrolled

Chemoradiation1 trial

PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

Completed·CCentre Oscar Lambret·Phase 2·NCT02359968·106 enrolled

Adult Subject1 trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06917079·387 enrolled

Chimeric Antigen Receptor T-cell1 trial

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Recruiting·CCelyad Oncology SA·Phase 1·NCT03692429·49 enrolled

Locally Advanced Colon Cancer1 trial

Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

Not yet recruiting·MMaimónides Biomedical Research Institute of Córdoba·Phase 3·NCT06783491·1,083 enrolled

Stage II/III Colon Cancer1 trial

FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer

Completed·GGruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente·Phase 3·NCT00646607·3,756 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Active, not recruiting·IITM Solucin GmbH·Phase 3·NCT04919226·259 enrolled

Gastroesophageal Junction (GEJ) Cancers1 trial

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03662659·274 enrolled

Pseudomyxoma Peritonei1 trial

A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis

Terminated·WWashington University School of Medicine·Phase 2·NCT00352755·18 enrolled

Gastric Adenocarcinoma1 trial

NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT02486601·55 enrolled

Randomized Controlled Trial1 trial

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Terminated·PPeking University·Phase 2/3·NCT05171166·18 enrolled

Hepatocellular Carcinoma1 trial

Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria

Unknown status·SSun Yat-sen University·Phase 3·NCT03469479·252 enrolled

Cancer of the Esophagus1 trial

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

Completed·TTranslational Oncology Research International·Phase 2·NCT00591123·38 enrolled

Metastasis1 trial

A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis

Completed·YYonsei University·Phase 2·NCT01269229·32 enrolled

PET1 trial

PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

Completed·IIntegraGen SA·Phase 3·NCT03362684·1,808 enrolled

Intensity-modulated Radiation Therapy1 trial

Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00613080·79 enrolled

Rectal Carcinoma1 trial

Neo-Adjuvant FOLFOX for Rectal Carcinoma

Terminated·—·Phase 2·NCT00832299·2 enrolled

Adjuvant Chemotherapy1 trial

Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More

Recruiting·—·Phase 3·NCT06293625·150 enrolled

Organ Preservation1 trial

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Recruiting·MMedical College of Wisconsin·Phase 1·NCT04808323·22 enrolled

Melanoma1 trial

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02009449·353 enrolled

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 (Spevatamig) Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

Recruiting·PPhanes Therapeutics·Preclinical·NCT05482893·258 enrolled

CRC (Colorectal Cancer)1 trial

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Recruiting· Incyte logo

Incyte·Phase 3·NCT07284849·700 enrolled

Colorectal Neoplasms1 trial

A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06663319·260 enrolled

Esophageal Adenocarcinoma1 trial

ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07221149·690 enrolled

Solid Tumor, Adult1 trial

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06625775·392 enrolled

Sources

References

[1]
ClinicalTrials.gov — 80 trial records for FOLFOX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

FOLFOX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Metastatic Colorectal Cancer15 trials

Pancreatic Cancer5 trials

Gastric Cancer4 trials

Colorectal Cancer4 trials

Chemotherapy3 trials

Intrahepatic Cholangiocarcinoma3 trials

Locally-advanced Rectal Cancer3 trials

Adenocarcinoma2 trials

Advanced or Metastatic Solid Tumors2 trials

Esophageal Cancer2 trials

Rectal Cancer2 trials

Stage III Colon Cancer2 trials

Advanced1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Colon Cancer1 trial

Paclitaxel1 trial

Colorectal Carcinoma1 trial

Cancer1 trial

Efficacy1 trial

Biliary Tract Cancer1 trial

Patients With Solid Tumors1 trial

Chemoradiation1 trial

Adult Subject1 trial

Chimeric Antigen Receptor T-cell1 trial

Locally Advanced Colon Cancer1 trial

Stage II/III Colon Cancer1 trial

Pancreatic Neuroendocrine Tumor1 trial

Gastroesophageal Junction (GEJ) Cancers1 trial

Pseudomyxoma Peritonei1 trial

Gastric Adenocarcinoma1 trial

Randomized Controlled Trial1 trial

Hepatocellular Carcinoma1 trial

Cancer of the Esophagus1 trial

Metastasis1 trial

PET1 trial

Intensity-modulated Radiation Therapy1 trial

Rectal Carcinoma1 trial

Adjuvant Chemotherapy1 trial

Organ Preservation1 trial

Melanoma1 trial

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

CRC (Colorectal Cancer)1 trial

Colorectal Neoplasms1 trial

Esophageal Adenocarcinoma1 trial

Solid Tumor, Adult1 trial

References

Drug Info

Quick Facts

Related News